ANRS IPERGAY Trial: Prophylaxis in men at risk of HIV

anrs ipergay trial hiv
2015 ANRS IPERGAY TRIAL On-demand preexposure prophylaxis in men at high risk for HIV-1 infection Multicenter randomized, placebo controlled trial Objective: To assess if on-demand pre-exposure prophylaxis around the time of sex reduce the transmission of HIV Among men who have sex with men and are at high risk for HIV transmission 400 Men, age ≥18, HIV-1 & 2 negative having anal sex with ≥2 partners in prior 6 months without consistent condom use were randomized to: emtricitabine- Matched tenofovir prophylaxis VS placebo (n=201) (n=199) 0.91 PRIMARY OUTCOME HIV-1 infection (per 100 person-years) RR 86%; 95% CI 40-98%; P=0.002 153 SECONDARY OUTCOME 6.60 Monthly pills taken (median) 15 P=0.57 Post-exposure prophyaxis 31 during the study (N) 25 P=0.37 Conclusion: The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events. Molina JM, et al. | NEJM, 2015; 373:2237-2246


Comments are closed.